Sutro Biopharma, Inc. (STRO)
| Market Cap | 577.70M |
| Revenue (ttm) | 102.48M |
| Net Income (ttm) | -191.09M |
| Shares Out | 16.57M |
| EPS (ttm) | -22.49 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 190,905 |
| Open | 33.40 |
| Previous Close | 33.59 |
| Day's Range | 31.61 - 35.95 |
| 52-Week Range | 6.74 - 36.00 |
| Beta | 1.31 |
| Analysts | Buy |
| Price Target | 28.00 (-19.7%) |
| Earnings Date | May 11, 2026 |
About STRO
Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, pancreatic ductal adenocarcin... [Read more]
Financial Performance
In 2025, Sutro Biopharma's revenue was $102.48 million, an increase of 65.18% compared to the previous year's $62.04 million. Losses were -$191.09 million, -15.99% less than in 2024.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for STRO stock is "Buy." The 12-month stock price target is $28.0, which is a decrease of -19.70% from the latest price.
News
Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights
– Dosed three cohorts in Phase 1 trial of STRO-004, potential best-in-class Tissue Factor (TF) ADC; on track to report initial clinical data in mid-2026 –
Sutro Biopharma Transcript: The Citizens Life Sciences Conference 2026
A major strategic pivot has accelerated a differentiated ADC pipeline, with STRO-004 in phase I and two more programs set for INDs this year. The cell-free platform enables higher drug exposure and safety, while dual payload ADCs aim to overcome resistance. Key data and milestones are expected within the next 12 months.
Sutro Biopharma Transcript: TD Cowen 46th Annual Health Care Conference
A new leadership team has transformed operations, extended financial runway, and accelerated clinical programs, notably advancing a differentiated ADC pipeline. The lead program, STRO-004, is in clinical trials with top-line data expected mid-year, aiming for broad tumor impact and improved safety.
Sutro Biopharma to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format ...
Sutro Biopharma Announces Pricing of $110.0 million Underwritten Offering
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (Nasdaq: STRO), a clinical-stage oncology company pioneering site-specific and novel-format ...
Sutro Biopharma Transcript: 44th Annual J.P. Morgan Healthcare Conference
A strategic pivot and new leadership have transformed the company, streamlining operations and accelerating a differentiated ADC pipeline. Key programs, including single and dual payload ADCs, are advancing rapidly, with robust preclinical and early clinical data, extended cash runway, and strategic partnerships supporting future growth.
Sutro Biopharma Transcript: Piper Sandler 37th Annual Healthcare Conference
Significant progress was highlighted in ADC platform innovation, with rapid clinical advancement of STRO-004 and plans for multiple new INDs. Dual payload and immunostimulatory ADCs are key pipeline differentiators, supported by a strong financial runway into 2027.
Sutro Biopharma Transcript: R&D Day 2025
A diversified ADC pipeline is advancing with STRO-004 in the clinic, STRO-006 and PTK7 dual payload ADCs targeting INDs in 2026-2027, and strong preclinical data supporting broad tumor applications. Platform innovations and partnerships have extended the financial runway and positioned the company for multiple clinical milestones in 2026.
Sutro Biopharma Reports Third Quarter 2025 Financial Results and Business Highlights
– Company announces U.S. FDA clearance of Investigational New Drug (IND) application for STRO-004, its potential best-in-class Tissue Factor ADC; Expects to dose first patient before year-end –
Sutro Biopharma to Host Virtual Research & Development Day on November 12, 2025
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug ...
Sutro Biopharma Announces Participation at the 16th Annual World ADC Conference
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug ...
Sutro Biopharma Announces Operational Restructuring Intended to Extend Cash Runway through Key Milestones
– Extends cash runway into at least mid-2027 – SOUTH SAN FRANCISCO, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneeri...
Sutro Biopharma Transcript: Wells Fargo 20th Annual Healthcare Conference 2025
The company has pivoted to an early-stage ADC pipeline, advancing STRO-004 and STRO-006 with innovative payload and linker technologies. Preclinical data show strong efficacy and safety, with IND filings and clinical entry expected this year. R&D Day will highlight progress and future plans.
Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business Highlights
– On track to initiate FIH study with STRO-004, potential best-in-class Tissue Factor ADC, in the second half of 2025 –
Sutro Biopharma Transcript: Jefferies Global Healthcare Conference 2025
A proprietary ADC platform enables broad optimization and supports both single and dual payload programs, with three INDs planned over the next three years. Lead programs show strong preclinical differentiation and safety, while strategic partnerships and a solid cash position extend the financial runway.
Sutro Biopharma Transcript: TD Cowen's 6th Annual Oncology Innovation Summit
Management is shifting focus to next-generation ADCs, leveraging lessons from Luvelta to enhance product design and safety. Dual payload ADCs show promise in overcoming resistance, with STRO-004 and STRO-006 advancing toward clinical trials and demonstrating strong safety and exposure profiles.
Sutro Biopharma Transcript: Bank of America 2025 Healthcare Conference
A strategic shift deprioritized a late-stage program to focus on next-generation ADCs targeting hard-to-reach tumor antigens, with three INDs planned over the next three years. The platform's technological advances and collaborations support a robust pipeline and extended financial runway.
Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights
- Sharpened product candidate focus on its next-generation ADC portfolio, following strategic review and pipeline reprioritization -
Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025
- Preclinical findings show STRO-004's promising anti-tumor activity and favorable safety profile - - Preclinical findings show STRO-004's promising anti-tumor activity and favorable safety profile -
Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025
- The late-breaking oral presentation at SGO 2025 highlights consistent response rates observed in patients across all levels of FRα expression of 25% or greater - - The late-breaking oral presentatio...
Penny Stock Sutro Biopharma Cuts Costs, Refocuses Pipeline
On Thursday, Sutro Biopharma, Inc. STRO prioritized its antibody-drug conjugates (ADC) pipeline, including three wholly-owned preclinical programs in its next-generation ADC pipeline.
Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights
– Sutro announced a strategic portfolio review resulting in prioritization of wholly-owned next-generation ADC programs; Key management changes announced as part of transition –
Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline
– Sutro will rapidly advance next-generation exatecan and dual-payload ADC programs; luveltamab tazevibulin development to be deprioritized as Sutro continues to seek a partner –
Sutro Biopharma Earnings Call Transcript: Q4 2024
Strategic restructuring prioritizes three next-gen ADC programs, extends cash runway into Q4 2026, and reduces workforce by 50%. Luvelta is deprioritized with active outlicensing, while pipeline INDs are planned for 2025–2027.
Sutro Biopharma Transcript: TD Cowen 45th Annual Healthcare Conference
Cell-free manufacturing enables differentiated ADCs with higher potency, safety, and dual payload capabilities. Lead candidate Luvelta is advancing in phase III trials, with a BLA filing targeted for 2027 and strong financial backing. Dual payload ADCs and strategic partnerships position the pipeline for broad clinical impact.